Evidence map›Paper›PMID 24485587›Full record

Trial reportSchizophrenia research2014

d-Cycloserine augmentation of cognitive remediation in schizophrenia.

Christopher K Cain, Margaret McCue, Iruma Bello, Timothy Creedon, Dei-In Tang, Eugene Laska, Donald C Goff

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00963924 (A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia), which is not on this map. Cited by 39 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 5 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00963924 nacompletednot on this map

A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

TypeinterventionalSponsorMassachusetts General HospitalRan2009 to 2011Enrolled54ConditionsSchizophreniaArmsD-cycloserine, Placebo, Cognitive Remediation
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Natural Medicines for Psychotic Disorders: A Systematic Review.The Journal of nervous and mental disease · 2018
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Trial
  13. Novel drug treatments for schizophrenia.Nature reviews. Drug discovery · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christopher K CainNathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA; Child and Adolescent Psychiatry Department, NYU Langone Medical Center, One Park Avenue, New York City, NY 10016, USA. Electronic address: ccain@nki.rfmh.org.
Margaret McCueNathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Electronic address: mmccue@nki.rfmh.org.
Iruma BelloPsychiatry Department, NYU Langone Medical Center, 550 First Avenue, New York City, NY 10016, USA. Electronic address: iruma.bello@nyumc.org.
Timothy CreedonPsychiatry Department, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA. Electronic address: tcreedon@brandeis.edu.
Dei-In TangNathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Electronic address: tang@nki.rfmh.org.
Eugene LaskaNathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Electronic address: laska@nki.rfmh.org.
Donald C GoffPsychiatry Department, NYU Langone Medical Center, 550 First Avenue, New York City, NY 10016, USA; Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Electronic address: DGoff@nki.rfmh.org.
Nathan Kline Institute for Psychiatric Research · USNYU Langone Health · USHarvard University · US

Funding

NMDA RECEPTOR FUNCTION IN SCHIZOPHRENIAP50MH060450 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI COYLE, JOSEPH T. · 2000 to 2010
$15.4M
New Treatment and Mechanisms in SchizophreniaK24MH002025 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI GOFF, DONALD C. · 2001 to 2011
$1.6M
From Fear Reactions to Instrumental Action: Brain Regions and Beta BlockersR21MH097125 · NIMH · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI CAIN, CHRISTOPHER KENNETH · 2012 to 2013
$430k
NIMH NIH HHS K24 MH002025NIMH NIH HHS P50 MH060450NIMH NIH HHS P50 MH60450NIMH NIH HHS R21 MH097125
6 · The paper itself

Abstract

d-Cycloserine (DCS) has been shown to enhance memory and, in a previous trial, once-weekly DCS improved negative symptoms in schizophrenia subjects. We hypothesized that DCS combined with a cognitive remediation (CR) program would improve memory of a practiced auditory discrimination task and that gains would generalize to performance on unpracticed cognitive tasks. Stable, medicated adult schizophrenia outpatients participated in the Brain Fitness CR program 3-5 times per week for 8weeks. Subjects were randomly assigned to once-weekly adjunctive treatment with DCS (50mg) or placebo administered before the first session each week. Primary outcomes were performance on an auditory discrimination task, the MATRICS cognitive battery composite score and the Scale for the Assessment of Negative Symptoms (SANS) total score. 36 subjects received study drug and 32 completed the trial (average number of CR sessions=26.1). Performance on the practiced auditory discrimination task significantly improved in the DCS group compared to the placebo group. DCS was also associated with significantly greater negative symptom improvement for subjects symptomatic at baseline (SANS score ≥20). However, improvement on the MATRICS battery was observed only in the placebo group. Considered with previous results, these findings suggest that DCS augments CR and alleviates negative symptoms in schizophrenia patients. However, further work is needed to evaluate whether CR gains achieved with DCS can generalize to other unpracticed cognitive tasks.

Indexed as

SchizophreniaAcoustic StimulationAdultAntimetabolitesCognition DisordersCognitive Behavioral TherapyCycloserineDiscrimination, PsychologicalFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuropsychological TestsPsychiatric Status Rating ScalesSingle-Blind MethodAntimetabolitesCycloserineCognitive remediationd-CycloserineMATRICSMemorySANSSchizophrenia

Identifiers

PMID24485587
PMCPMC4547356
OpenAlexW2036522383

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.